Diabetes-related metabolic perturbations in cardiac myocytePerturbations métaboliques des cardiomyocytes liées au diabète
References (63)
- et al.
New type of cardiomyopathy associated with diabetic glomerulosclerosis
Am J Cardiol.
(1972) - et al.
Role of diabetes in congestive heart failure: the Framingham study
Am J Cardiol.
(1974) - et al.
Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths
Lancet
(2002) - et al.
Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy: the Framingham Heart Study
Am J Cardiol.
(1991) - et al.
Myocardial utilization of carbohydrate and lipids
Prog Cardiovasc Dis.
(1972) - et al.
Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator activated receptor α (PPARα)
J Biol Chem.
(1998) - et al.
The role of the peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac lipid metabolism
Prostaglandins Leukot Essent Fatty Acids
(1999) - et al.
Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity
J Biol Chem.
(2000) - et al.
A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase
J Biol Chem.
(2002) - et al.
Insulin signalling pathways in time and space
Trends Cell Biol.
(2002)
Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signalling pathways
J Mol Cell Cardiol.
High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5’AMP-activated protein kinase inhibition of acetyl CoA carboxylase
J Biol Chem.
Insulin antagonizes AMP-activated protein activation by ischemia or anoxia in rat hearts without affecting total adenine nucleotides
FEBS Lett.
UCP3 gene expression does not correlate with muscle oxidation rates in troglitazone-treated Zucker fatty rats
Biochim. Biophys. Acta.
Fatty acid metabolism is enhanced in type 2 diabetic hearts
Biochim Biophys Acta
Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy
J Mol Cell Cardiol.
Activation of Na+-H+ antiporter (NHE-1), gene expression during growth, hypertrophy and proliferation of the rabbit cardiovascular system
J Mol Cell Cardiol.
Diabetes mellitus: a major risk factor for cardiovascular disease
Circulation
Diabetic cardiomyopathy: fact or fiction?
Heart
Impact of diabetes on cardiac structure and function: the strong heart study
Circulation
Diabetic cardiomyopathy. The search for a unifying hypothesis
Circ Res.
Nuclear receptor signaling and cardiac energetics
Circ Res.
Nuclear receptors and lipid physiology: opening the X-files
Science
Lipid metabolism, metabolic diseases, and peroxisome proliferators-activated receptors
Endocrinology
The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus
J Clin Invest.
Cardiac lipid accumulation associated with diastolic dysfunction in obese mice
Endocrinology
Lipotoxic heart disease in obese rats: implications for human disease
Proc Natl Acad Sci USA
Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart
Diabetes
A critical for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation of phenotype by dietary fat content
Proc Natl Acad Sci USA
Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM
Diabetes
What if Minkowski had been ageusic? An alternative angle on diabetes
Science
Cited by (41)
Neutrophil-to-lymphocyte ratio is associated with coronary microvascular dysfunction in type 2 diabetes mellitus patients
2021, Diabetes Research and Clinical PracticeCola nitida infusion modulates cardiometabolic activities linked to cardiomyopathy in diabetic rats
2021, Food and Chemical ToxicologyCitation Excerpt :The presence of eicosanoic acid and cis-5,8,11,14,17-eicosapentaenoic acid may be a defensive response by the heart to mitigate the onset of lipotoxicity. The high concentrations of fatty esters also corroborate previous reports on their implication in the pathophysiology of diabetic cardiomyopathy (Dobrin and Lebeche, 2010; Feuvray and Darmellah, 2008; Feuvray and Le Plessis Robinson, 2010). The low cardiac cholesterol level may insinuate impaired cholesterol transportation to the heart from the liver which also denotes an alteration in cardiac lipid metabolites.
Treatment of Diabetes in People With Heart Failure
2018, Canadian Journal of DiabetesCitation Excerpt :Three beta blockers have been shown to reduce morbidity and mortality for people with heart failure, reduced EF and diabetes: carvedilol, bisoprolol and metoprolol succinate. While overall glycemic control generally improves as heart failure is treated with evidence-based therapies, (30–32), carvedilol, in comparison to other beta blockers, has been shown to specifically improve glycemic control (19,33). For this reason, some clinicians prefer carvedilol as the beta blocker of choice in people with diabetes and heart failure.
Glucose as an agent of post-translational modification in diabetes - New cardiac epigenetic insights
2015, Life SciencesCitation Excerpt :For the first time, we have recently reported the synthetic incorporation of AGEs into collagen peptides which can be used to dissect the chemical, physical and mechanical properties of AGE modified collagens and related proteins (Woods et al., 2012). In a diabetic setting, hyperglycemia is linked to disturbed cardiomyocyte intracellular glucose handling (Feuvray and Darmellah, 2008; Montessuit and Lerch, 1833). It is clear that hyperglycemia modifies the intracellular glucose signaling milieu, but mechanistically the details are not well resolved.
Traitement du diabète chez les personnes atteintes d'insuffisance cardiaque
2013, Canadian Journal of DiabetesCitation Excerpt :On a démontré que trois bêta-bloquants, le carvédilol, le bisoprolol et le métoprolol, réduisaient la morbidité et la mortalité chez les patients diabétiques présentant une insuffisance cardiaque. Selon les données cumulées à ce jour, le contrôle glycémique général est meilleur au fur et à mesure que le syndrome d'insuffisance cardiaque s'améliore sous l'effet d'un traitement (24–26). Le carvédilol a été associé à un meilleur contrôle glycémique comparativement aux autres bêta-bloquants.
Treatment of Diabetes in People with Heart Failure
2013, Canadian Journal of Diabetes